Brokerages forecast that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will post $1.28 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.53 and the lowest estimate coming in at $1.11. Alexion Pharmaceuticals reported earnings of $1.26 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 1.6%. The business is expected to report its next quarterly earnings report on Thursday, February 15th.
On average, analysts expect that Alexion Pharmaceuticals will report full year earnings of $5.67 per share for the current fiscal year, with EPS estimates ranging from $5.50 to $5.90. For the next year, analysts anticipate that the firm will post earnings of $7.11 per share, with EPS estimates ranging from $6.49 to $8.64. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.23 earnings per share.
Several equities analysts have issued reports on ALXN shares. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research note on Tuesday, October 31st. Credit Suisse Group restated a “buy” rating and issued a $166.00 price objective on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Raymond James Financial restated an “outperform” rating and issued a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $154.00.
Alexion Pharmaceuticals (NASDAQ ALXN) opened at $122.71 on Friday. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34. The stock has a market cap of $27,410.00, a price-to-earnings ratio of 54.78, a price-to-earnings-growth ratio of 1.03 and a beta of 1.17.
In other news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the sale, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.35% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ALXN. Valeo Financial Advisors LLC purchased a new position in Alexion Pharmaceuticals during the third quarter worth about $147,000. Dupont Capital Management Corp purchased a new position in Alexion Pharmaceuticals during the third quarter worth about $156,000. BT Investment Management Ltd purchased a new position in Alexion Pharmaceuticals during the third quarter worth about $165,000. YorkBridge Wealth Partners LLC raised its holdings in Alexion Pharmaceuticals by 221.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 982 shares in the last quarter. Finally, Beacon Investment Advisory Services Inc. purchased a new position in Alexion Pharmaceuticals during the third quarter worth about $201,000. 94.26% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “$1.28 Earnings Per Share Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://transcriptdaily.com/2018/01/14/1-28-earnings-per-share-expected-for-alexion-pharmaceuticals-inc-alxn-this-quarter.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.